A Phase 3 interventional study of Trastuzumab Injectable Solution and Trastuzumab Injectable Product in Breast Cancer, sponsored by Spanish Breast Cancer Research Group. Completed at 27 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-05.
Sponsored by Spanish Breast Cancer Research Group · Phase 3, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 88th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 199th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 26 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 166 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Spanish Breast Cancer Research Group is the lead sponsor of 50 studies on the registry; 4 are open to participants now.
49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group: 4 open now, 7 under way, none of them phase 3. Of 41 finished, 20 (49%) have results posted.
Among the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group, this one is the 16th largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2013, is one of 12 in phase 3, and was the 27th registered.
Spanish Breast Cancer Research Group’s Breast Neoplasms studies by the year they started, since 1999.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Spanish Breast Cancer Research Group’s 49 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration through the vial or device self-administration in patients with disseminated breast cancer HER2.
Approximately 195 patients will be included to receive subcutaneous trastuzumab a fixed dose of 600 mg every 3 weeks for 4 cycles (2 administered from the injection of a vial with a syringe and 2 with the injection device). Following administration of these four cycles, the patient will decide whether or not to continue with the subcutaneous formulation of trastuzumab every 3 weeks until progression (out of the study). Since the randomization in the study until the start with subcutaneous trastuzumab, patients will receive a treatment cycle of intravenous trastuzumab as usual.
Main objective: Proportion of patients indicate a preference for the use of subcutaneous vs intravenous trastuzumab.
This principal primary objective will be analyzed with the answers to questionnaire of experiences and preferences of the patients (Principal endpoint) The duration of the study has been estimated after 34 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive confirmed. The criteria for positivity HER 2 are:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
Drug: Trastuzumab Injectable Solution · Drug: Trastuzumab Injectable Product · Drug: Trastuzumab Injection
Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
Drug: Trastuzumab Injectable Solution · Drug: Trastuzumab Injectable Product · Drug: Trastuzumab Injection
Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
Also known as: Herceptin
Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
Also known as: Herceptin
Powder for concentrate for solution for infusion. 1 cycle
Also known as: Herceptin
Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference
The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.
Time frame: Up to 12 weeks
Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference
The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.
Time frame: Up to 12 weeks
Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference
The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.
Time frame: Up to 12 weeks
Percentage of Medical Staff Subcutaneous Device vs. Vial Preference
The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.
Time frame: Up to 12 weeks
Patient Time in Healthcare Unit and Sitting in Chair/Bed
Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit. Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.
Time frame: An average of 4 months
The Number of Participants Who Experienced Adverse Events (AE)
Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.
Time frame: Through study treatment, an average of 12 weeks
Eligible patients, from the randomization and before starting subcutaneous trastuzumab (SC-t), received an additional intravenous (IV-t) cycle. After receiving this cycle, patients started the treatment with the study medication, SC-t at a fixed dose of 600 mg every 3 weeks (+3 days) for 4 cycles (2 administered from the injection of a vial in a syringe and 2 with the single-use injection device \[SID\]), being randomized 1:1 in two arms of treatment without washout period.
| Milestone | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial |
|---|---|---|
| Started | 81 | 85 |
| Completed | 76 | 83 |
| Not completed | 5 | 2 |
| Withdrew: Not complete at least 2 questionaries | 4 | 2 |
| Withdrew: Not receive study treatment | 1 | 0 |
The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.
| Participants | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial |
|---|---|---|
| Subcutaneous | 66 | 71 |
| Intravenous | 6 | 5 |
| No preference | 4 | 7 |
The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.
| Participants | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial |
|---|---|---|
| Device | 46 | 44 |
| Vial | 20 | 20 |
| No preference | 4 | 13 |
| Not answered | 2 | 3 |
The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.
| Participants | Both Arms |
|---|---|
| Subcutaneous | 34 |
| Intravenous | 0 |
| No differences | 4 |
| Not answered | 1 |
The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.
| Participants | Both Arms |
|---|---|
| Preferred device | 20 |
| Preferred vial | 11 |
| No Preference | 8 |
Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit. Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.
| minutes | Both Arms: Intravenous-Trastuzumab (IV-t) | Both Arms: Subcutaneous-Trastuzumab Vial (SC-t Vial) | Boths Arms: Subcutaneous-Trastuzumab Device (SC-t SID) |
|---|---|---|---|
| Healthcare unit | 203 ± 123.57 | 144.84 ± 121.99 | 122.9 ± 112.33 |
| Sitting in the infusion/treatment chair/bed | 100.01 ± 56.34 | 31.6 ± 28.74 | 24.75 ± 15.42 |
Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.
| Participants | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial |
|---|---|---|
| The Number of Participants Who Experienced Adverse Events (AE) | 76 | 84 |
Collected over Through study treatment, an average of 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: T-IV + T-SC Vial + T-SC Device | 0/81 (0%) | 2/81 (2.5%) | 76/81 (93.8%) |
| Arm B: T-IV + T-SC Device + T-SC Vial | 0/85 (0%) | 10/85 (11.8%) | 84/85 (98.8%) |
| Event | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial |
|---|---|---|
| FeverGeneral disorders | 1/81 | 0/85 |
| HematuriaRenal and urinary disorders | 1/81 | 0/85 |
| Heart failureCardiac disorders | 0/81 | 1/85 |
| Nodule in left breastReproductive system and breast disorders | 0/81 | 1/85 |
| ColdInfections and infestations | 0/81 | 1/85 |
| Nodule in right breastReproductive system and breast disorders | 0/81 | 1/85 |
| Lack of strength in left legMusculoskeletal and connective tissue disorders | 0/81 | 1/85 |
| Catheter related infection (Bacteriemia)Infections and infestations | 0/81 | 1/85 |
| StrokeNervous system disorders | 0/81 | 1/85 |
| Surgery for surgical castrationReproductive system and breast disorders | 0/81 | 1/85 |
| Event | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 27/81 | 32/85 |
| Creatinine increasedInvestigations | 13/81 | 17/85 |
| Aspartate aminotransferase increasedInvestigations | 15/81 | 17/85 |
| White blood cells decreasedInvestigations | 15/81 | 17/85 |
| Alanine aminotransferase increasedInvestigations | 16/81 | 10/85 |
| FatigueGeneral disorders | 10/81 | 16/85 |
| Alkaline phosphatase increasedInvestigations | 12/81 | 15/85 |
| Neutrophil count decreasedInvestigations | 13/81 | 13/85 |
| Injection site reactionGeneral disorders | 9/81 | 6/85 |
| Platelet count decreasedInvestigations | 4/81 | 8/85 |
| Age, Continuous(years) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| Median | 63 (35 to 93) | 58 (38 to 85) | 60 (35 to 93) |
| Sex: Female, Male(Participants) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| Female | 81 | 85 | 166 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| Caucasian | 78 | 83 | 161 |
| Black | 1 | 0 | 1 |
| Hispanic | 1 | 0 | 1 |
| Arabian | 1 | 2 | 3 |
| Menopausal status(Participants) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| Premenopausal | 8 | 12 | 20 |
| Postmenopausal | 73 | 73 | 146 |
| Eastern Cooperative Oncology Group (ECOG) performance status(Participants) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| ECOG 0 | 63 | 61 | 124 |
| ECOG 1 | 17 | 24 | 41 |
| ECOG 2 | 1 | 0 | 1 |
| Estrogen Receptor(Participants) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| Positive | 46 | 60 | 106 |
| Negative | 35 | 25 | 60 |
| Progesterone Receptor(Participants) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| Negative | 50 | 38 | 88 |
| Positive | 31 | 47 | 78 |
| Time with IV trastuzumab for metastasis at registration(years) | Arm A: T-IV + T-SC Vial + T-SC Device | Arm B: T-IV + T-SC Device + T-SC Vial | Total |
|---|---|---|---|
| Median | 1.9 (0.35 to 13.67) | 1.78 (0.34 to 14.05) | 1.8 (0.34 to 14.05) |
9 further baseline measures are reported on the registry.
Ran from Sep 2013 to primary completion in Nov 2016, 38 months.
Results were first posted in Feb 2021, 4 years 2 months after primary completion.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's 38 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab
Spanish Breast Cancer Research Group